Madagascar

In Madagascar, PSI works with the Malagasy people to promote malaria and HIV prevention, sexual and reproductive health and maternal, newborn and child health to ensure that everyone in Madagascar receives quality healthcare.

BP 7748
Immeuble Fiaro
Escalier D 2ème étage
Ampefiloha Antananarivo 101
Madagascar

Phone: + 261-20-22-629-84
info@psi.mg

Our Presence in
Madagascar

PSI Madagascar

PSI Madagascar was founded in 1998 to help priority populations and those with low incomes gain access to essential health products, services and information. Since then, its activities have expanded to include programs focused on child survival, malaria, reproductive health and HIV.

How we
work

01
Asset 17

Consumer
Led

02
Asset 26

Market Development

03

Program
Design

04
Asset 9

Social
Enterprise

Our
Impact

PSI Madagascar estimates that in 2018, its products and services provided 2,089,278 years of healthy life for the people of Madagascar, including:

1,546,066

years of life free from malaria

313,392

years of healthy life provided by its sexual and reproductive health programs

146,249

years of life free of HIV and other sexually transmitted infections

62,678

years of healthy life for new mothers and their babies

20,893

years of quality sanitation and clean water

Practice Areas
We Focus On

PSI Madagascar provides quality sexual and reproductive health services to reach Malagasy national objectives, as well as the international Family Planning 2020 goals, and to expand contraceptive method choice across the country. PSI Madagascar works with the Malagasy government to integrate innovative sexual and reproductive health programs into private networks and public facilities to reach rural and remote areas with mobile clinic services.

To reduce maternal mortality and morbidity, PSI Madagascar expands access to quality post-abortion care services and harm reduction counseling in 18 regions of the country. PSI Madagascar also works with the Malagasy government to integrate innovative maternal health programs into private networks and public facilities. As part of this work, PSI Madagascar successfully registered Ace Miso as the first misoprostol for gynecological indications and distributes it nationwide.

As a principal recipient of the Global Fund, PSI Madagascar focuses on prevention activities to reduce the number of new HIV infections among key populations and the general population by the end of 2020. PSI Madagascar’s work expands facility and community-based HIV prevention, testing, treatment and care services for key populations in 22 regions.

To reach the goal of targeted geographic and progressive malaria in Madagascar, PSI Madagascar works with the Malagasy Ministry of Health and the National Malaria Control Program to provide access to high quality rapid diagnostic tests and antimalarial drugs, as well as insecticide-treated nets. PSI Madagascar also supports microscopy diagnosis improvement and surveillance for the elimination of malaria in two districts.

Featured Projects

Response for HIV and for Sexually Transmitted Infections in Madagascar

Donor: Global Fund to Fight AIDS, Tuberculosis and Malaria

+ Read More

Support for International Family Planning Organizations (SIFPO2)

Donor: USAID

+ Read More

New Funding Model 2 Malaria: Progressive Elimination of Malaria in Madagascar

Donor: Global Fund to Fight AIDS, Tuberculosis and Malaria

+ Read More

PMI Impact Malaria

Donor: US President’s Malaria Initiative

+ Read More

PMI VectorLink

Donor: US President’s Malaria Initiative (PMI)

Project Lead: Abt Associates

+ Read More

Our
Leadership

Daniel Crapper

Country Representative PSI Madagascar

Freddy Lokosa

Deputy Country Representative PSI Madagascar

Latest
Updates

Discover what's happening at PSI

Youth Tell All: Young and Living in a Pandemic

By Christine Massawe, A360 Young Designer/Youth Officer, PSI Tanzania    Access to contraception is one of many tools that equips young people like me with

+ Read More

Ask Kelly: ETHICS DURING COVID-19- Returning to In-person Research 

By: Kelly O’Keefe, Research Ethics Senior Technical Advisor, PSI; Jennifer Wheeler, Deputy Director for Research, PSI; and Kristen Little, Senior Technical Advisor, Strategic Research, PSI Since the

+ Read More

In Memoriam to Bill Gates, Sr.

By Karl Hofmann, President & CEO, PSI  Let me add our voices to those who have paid tribute to Bill Gates, Sr. His remarkable contributions to the work of

+ Read More

Youth Contraceptive Programming: Learning from a Mid-Term Evaluation

As a learning project, PSI’s flagship adolescent sexual and reproductive health program, Adolescents 360 (A360) used its external 2018 mid-term evaluation (MTE) to support corrections

+ Read More

Infected and Affected: The Indirect Consequences of COVID-19 in Central America

By Jennifer Wheeler, PSI Deputy Director, Research, Paola Letona, PSI Evidence Regional Director, LAC, and Sussy Lungo, Regional Executive Director, Asociación PASMO “When you are

+ Read More

Five Market Indicators that Signal the Hormonal IUS will take off

By Kendal Danna, PSI Technical Advisor, Reproductive Health  In 2017, with USAID support, PSI began piloting the introduction of the hormonal Intrauterine System (IUS), also

+ Read More